logo

We evaluated an inhibitor of the LRRK 2 gene in patients with Parkinson’s. Oral treatment.
We continue the development of new treatments that aim to modify the natural history of the disease, slowing its progression.

Compartir:
CategoryUncategorized

No dude en llamarnos 1-+34 935 656 000